Sort   by:  
 Page size 
TranscriptomicsTranscriptomic profiling of peripheral blood mononuclear cells from rheumatoid arthritis patients before tofacitinib treatment
This study explores the molecular mechanisms underlying variable therapeutic responses to tofacitinib in patients with rheumatoid arthritis (RA). Peripheral blood mononuclear cells (PBMCs) were collected from patients with active RA before tofacitinib treatment. Based on EULAR DAS28-defined clinical...
ORGANISM(S): Homo sapiens 
2026-01-09 | E-MTAB-16533 | biostudies-arrayexpress
ProteomicsRepurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment
The myeloma bone marrow microenvironment drives proliferation of malignant plasma cells and promotes resistance to therapy. Interleukin-6 (IL-6) and downstream JAK/STAT signaling are thought to be central components of these microenvironment-induced phenotypes. In a prior drug repurposing screen, we...
ORGANISM(S): Homo sapiens (Human) 
2018-10-24 | PXD006581 | Pride
Lc-msms Lfq Myeloma Bone marrow microenvironment Tofacitinib Human 
TranscriptomicsRNA-seq of murine mesenchymal stem cells during differentiation to osteoblasts, treated with tofacitinib or baricitinib against vehicle control
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease, characterized by synovial hyperplasia and progressive joint destruction. For treating inflammatory diseases, such as RA, the Janus kinase (JAK)-mediated signaling pathway has emerged as a therapeutic target. Therefore, JAK inhib...
ORGANISM(S): Mus musculus 
2020-02-12 | E-MTAB-8536 | biostudies-arrayexpress
TranscriptomicsRNA-seq of human colonic cancer cell line CACO-2 transfected 48h with siRNA targeting JAK1 (HJ1D8; HJ1D2) or JAK3 (HJ3D41; HMJ3D1) at 100pM final concentration using LipofectamineRNAiMAX or treated 48h with Tofacitinib (final concentration: 1µM) or Filgotinib (final concentration: 5µM) against controls (transfection medium: Opti-MEM, transfection mixt alone: Opti-MEM + Lipof., siMock, DMSO equivalent to volume added for Filgo 5µM).
Inflammatory bowel diseases are highly debilitating conditions that require constant monitoring and life-long medication. Current treatments are focused on systemic administration of immunomodulatory drugs, but they have a broad range of undesirable side-effects. The RNA interference is a highly spe...
ORGANISM(S): Homo sapiens 
2023-04-12 | E-MTAB-10348 | biostudies-arrayexpress
TranscriptomicsTofacitinib extends survival in a mouse model of ALS through NK cell-independent mechanisms
Background Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disease with few treatment options, rendering the development of new, effective therapeutics of critical importance. The immune system plays a substantial role in ALS pathology, with multiple cell populations implicated in ...
ORGANISM(S): Mus musculus 
2025-11-29 | E-MTAB-16025 | biostudies-arrayexpress
TranscriptomicsPathologic Immune Pathways in Psoriasis are Rapidly Attenuated by Tofacitinib Treatment: A Randomized Phase 2 Study in Patients with Moderate to Severe Psoriasis
Here we elucidate the molecular mechanism of tofacitinib, an oral Janus kinase inhibitor, in psoriasis. Tofacitinib exhibits a multi-tiered action, with early direct effects on keratinocytes and histological and transcriptomic improvement prior to IL-17 reduction. Twelve patients with plaque psorias...
ORGANISM(S): Homo sapiens 
2016-06-30 | E-GEOD-69967 | biostudies-arrayexpress
GenomicsStretch-Enhancers Delineate Disease-Associated Regulatory Nodes in T Cells
T Cell stretch-enhancers are vulnerable to Jak inhibitor tofacitinib Treatment of T cells with the Janus kinase (JAK) inhibitor, tofacitinib, disproportionately altered the expression of RA risk genes with stretech-enhancer (SE) structures.
ORGANISM(S): Homo sapiens 
2015-02-18 | E-GEOD-60482 | biostudies-arrayexpress
GenomicsAnalysis of rectal transcriptome in ulcerative colitis (UC) patients who received tofacitinib
Analysis of rectal transcriptome in ulcerative colitis (UC) patients who received tofacitinib
PRJNA1030353 | ENA
GenomicsEffects of tofacitinib and takinib on autoimmune pancreatitis in mice
Effects of tofacitinib and takinib on autoimmune pancreatitis in mice
PRJNA1162460 | ENA
GenomicsEvaluation of tofacitinib in cutaneous sarcoidosis [scRNA-seq]
Evaluation of tofacitinib in cutaneous sarcoidosis [scRNA-seq]
PRJNA715583 | ENA
Sort   by:  
 Page size